GSK plc (GLAXF) Stock Competitors & Peer Comparison
See (GLAXF) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GLAXF | $24.66 | +3.01% | 98.9B | 12.91 | $1.91 | +3.64% |
| BMYMP | $400.00 | -57.46% | 814.6B | 1777.78 | $0.23 | +4.37% |
| RHHBY | $51.45 | -0.24% | 329.5B | 19.98 | $2.56 | +3.03% |
| RHHVF | $411.25 | -2.70% | 327.4B | 20.21 | $20.35 | +3.02% |
| RHHBF | $408.08 | -0.64% | 324.8B | 20.04 | $20.36 | +3.04% |
| AZNCF | $189.90 | -1.35% | 294.4B | 31.49 | $6.03 | +1.41% |
| NVSEF | $144.88 | +0.70% | 276.4B | 20.76 | $6.98 | +3.27% |
| SNYNF | $87.71 | +1.26% | 105.4B | 19.03 | $4.61 | +5.52% |
| CHGCF | $47.72 | +2.82% | 78.5B | 28.75 | $1.66 | +3.78% |
| CHGCY | $23.14 | +0.00% | 75.8B | 27.73 | $0.83 | +3.55% |
Stock Comparison
GLAXF vs BMYMP Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, BMYMP has a market cap of 814.6B. Regarding current trading prices, GLAXF is priced at $24.66, while BMYMP trades at $400.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas BMYMP's P/E ratio is 1777.78. In terms of profitability, GLAXF's ROE is +0.33%, compared to BMYMP's ROE of +0.39%. Regarding short-term risk, GLAXF is less volatile compared to BMYMP. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.Check BMYMP's competition here
GLAXF vs RHHBY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, RHHBY has a market cap of 329.5B. Regarding current trading prices, GLAXF is priced at $24.66, while RHHBY trades at $51.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas RHHBY's P/E ratio is 19.98. In terms of profitability, GLAXF's ROE is +0.33%, compared to RHHBY's ROE of +0.29%. Regarding short-term risk, GLAXF is more volatile compared to RHHBY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check RHHBY's competition here
GLAXF vs RHHVF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, RHHVF has a market cap of 327.4B. Regarding current trading prices, GLAXF is priced at $24.66, while RHHVF trades at $411.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas RHHVF's P/E ratio is 20.21. In terms of profitability, GLAXF's ROE is +0.33%, compared to RHHVF's ROE of +0.41%. Regarding short-term risk, GLAXF is more volatile compared to RHHVF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check RHHVF's competition here
GLAXF vs RHHBF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, RHHBF has a market cap of 324.8B. Regarding current trading prices, GLAXF is priced at $24.66, while RHHBF trades at $408.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas RHHBF's P/E ratio is 20.04. In terms of profitability, GLAXF's ROE is +0.33%, compared to RHHBF's ROE of +0.29%. Regarding short-term risk, GLAXF is more volatile compared to RHHBF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check RHHBF's competition here
GLAXF vs AZNCF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, AZNCF has a market cap of 294.4B. Regarding current trading prices, GLAXF is priced at $24.66, while AZNCF trades at $189.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas AZNCF's P/E ratio is 31.49. In terms of profitability, GLAXF's ROE is +0.33%, compared to AZNCF's ROE of +0.23%. Regarding short-term risk, GLAXF is more volatile compared to AZNCF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check AZNCF's competition here
GLAXF vs NVSEF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, NVSEF has a market cap of 276.4B. Regarding current trading prices, GLAXF is priced at $24.66, while NVSEF trades at $144.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas NVSEF's P/E ratio is 20.76. In terms of profitability, GLAXF's ROE is +0.33%, compared to NVSEF's ROE of +0.32%. Regarding short-term risk, GLAXF is more volatile compared to NVSEF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check NVSEF's competition here
GLAXF vs SNYNF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, SNYNF has a market cap of 105.4B. Regarding current trading prices, GLAXF is priced at $24.66, while SNYNF trades at $87.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas SNYNF's P/E ratio is 19.03. In terms of profitability, GLAXF's ROE is +0.33%, compared to SNYNF's ROE of +0.14%. Regarding short-term risk, GLAXF is more volatile compared to SNYNF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check SNYNF's competition here
GLAXF vs CHGCF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, CHGCF has a market cap of 78.5B. Regarding current trading prices, GLAXF is priced at $24.66, while CHGCF trades at $47.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas CHGCF's P/E ratio is 28.75. In terms of profitability, GLAXF's ROE is +0.33%, compared to CHGCF's ROE of +0.23%. Regarding short-term risk, GLAXF is more volatile compared to CHGCF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check CHGCF's competition here
GLAXF vs CHGCY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, CHGCY has a market cap of 75.8B. Regarding current trading prices, GLAXF is priced at $24.66, while CHGCY trades at $23.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas CHGCY's P/E ratio is 27.73. In terms of profitability, GLAXF's ROE is +0.33%, compared to CHGCY's ROE of +0.24%. Regarding short-term risk, GLAXF is more volatile compared to CHGCY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check CHGCY's competition here
GLAXF vs BAYRY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, BAYRY has a market cap of 40.4B. Regarding current trading prices, GLAXF is priced at $24.66, while BAYRY trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas BAYRY's P/E ratio is -16.07. In terms of profitability, GLAXF's ROE is +0.33%, compared to BAYRY's ROE of -0.07%. Regarding short-term risk, GLAXF is more volatile compared to BAYRY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check BAYRY's competition here
GLAXF vs OTSKY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, OTSKY has a market cap of 34.4B. Regarding current trading prices, GLAXF is priced at $24.66, while OTSKY trades at $32.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas OTSKY's P/E ratio is 15.16. In terms of profitability, GLAXF's ROE is +0.33%, compared to OTSKY's ROE of +0.13%. Regarding short-term risk, GLAXF is more volatile compared to OTSKY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check OTSKY's competition here
GLAXF vs OTSKF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, OTSKF has a market cap of 34.2B. Regarding current trading prices, GLAXF is priced at $24.66, while OTSKF trades at $64.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas OTSKF's P/E ratio is 15.09. In terms of profitability, GLAXF's ROE is +0.33%, compared to OTSKF's ROE of +0.13%. Regarding short-term risk, GLAXF is more volatile compared to OTSKF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check OTSKF's competition here
GLAXF vs DSNKY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, DSNKY has a market cap of 27.9B. Regarding current trading prices, GLAXF is priced at $24.66, while DSNKY trades at $15.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas DSNKY's P/E ratio is 17.43. In terms of profitability, GLAXF's ROE is +0.33%, compared to DSNKY's ROE of +0.16%. Regarding short-term risk, GLAXF is more volatile compared to DSNKY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check DSNKY's competition here
GLAXF vs DSKYF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, DSKYF has a market cap of 27.8B. Regarding current trading prices, GLAXF is priced at $24.66, while DSKYF trades at $15.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas DSKYF's P/E ratio is 17.37. In terms of profitability, GLAXF's ROE is +0.33%, compared to DSKYF's ROE of +0.16%. Regarding short-term risk, GLAXF is more volatile compared to DSKYF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check DSKYF's competition here
GLAXF vs ALPMF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, ALPMF has a market cap of 25.4B. Regarding current trading prices, GLAXF is priced at $24.66, while ALPMF trades at $14.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas ALPMF's P/E ratio is 13.92. In terms of profitability, GLAXF's ROE is +0.33%, compared to ALPMF's ROE of +0.17%. Regarding short-term risk, GLAXF is more volatile compared to ALPMF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check ALPMF's competition here
GLAXF vs ALPMY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, ALPMY has a market cap of 23.8B. Regarding current trading prices, GLAXF is priced at $24.66, while ALPMY trades at $13.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas ALPMY's P/E ratio is 13.17. In terms of profitability, GLAXF's ROE is +0.33%, compared to ALPMY's ROE of +0.18%. Regarding short-term risk, GLAXF is more volatile compared to ALPMY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check ALPMY's competition here
GLAXF vs ORINY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, ORINY has a market cap of 21.4B. Regarding current trading prices, GLAXF is priced at $24.66, while ORINY trades at $37.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas ORINY's P/E ratio is 17.43. In terms of profitability, GLAXF's ROE is +0.33%, compared to ORINY's ROE of +0.49%. Regarding short-term risk, GLAXF is more volatile compared to ORINY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check ORINY's competition here
GLAXF vs GIKLY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, GIKLY has a market cap of 15B. Regarding current trading prices, GLAXF is priced at $24.66, while GIKLY trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas GIKLY's P/E ratio is 16.26. In terms of profitability, GLAXF's ROE is +0.33%, compared to GIKLY's ROE of +0.08%. Regarding short-term risk, GLAXF is more volatile compared to GIKLY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check GIKLY's competition here
GLAXF vs RCDTF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, RCDTF has a market cap of 12.2B. Regarding current trading prices, GLAXF is priced at $24.66, while RCDTF trades at $60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas RCDTF's P/E ratio is 22.81. In terms of profitability, GLAXF's ROE is +0.33%, compared to RCDTF's ROE of +0.24%. Regarding short-term risk, GLAXF is more volatile compared to RCDTF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check RCDTF's competition here
GLAXF vs CHJTF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, CHJTF has a market cap of 12B. Regarding current trading prices, GLAXF is priced at $24.66, while CHJTF trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas CHJTF's P/E ratio is 21.00. In terms of profitability, GLAXF's ROE is +0.33%, compared to CHJTF's ROE of +0.05%. Regarding short-term risk, GLAXF is more volatile compared to CHJTF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check CHJTF's competition here
GLAXF vs ORINF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, ORINF has a market cap of 11.7B. Regarding current trading prices, GLAXF is priced at $24.66, while ORINF trades at $82.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas ORINF's P/E ratio is 18.89. In terms of profitability, GLAXF's ROE is +0.33%, compared to ORINF's ROE of +0.49%. Regarding short-term risk, GLAXF is more volatile compared to ORINF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check ORINF's competition here
GLAXF vs CSPCY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, CSPCY has a market cap of 10.8B. Regarding current trading prices, GLAXF is priced at $24.66, while CSPCY trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas CSPCY's P/E ratio is 18.92. In terms of profitability, GLAXF's ROE is +0.33%, compared to CSPCY's ROE of +0.05%. Regarding short-term risk, GLAXF is more volatile compared to CSPCY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check CSPCY's competition here
GLAXF vs GIFOF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, GIFOF has a market cap of 8.7B. Regarding current trading prices, GLAXF is priced at $24.66, while GIFOF trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas GIFOF's P/E ratio is 12.46. In terms of profitability, GLAXF's ROE is +0.33%, compared to GIFOF's ROE of +0.08%. Regarding short-term risk, GLAXF is more volatile compared to GIFOF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check GIFOF's competition here
GLAXF vs GIFLF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, GIFLF has a market cap of 7.6B. Regarding current trading prices, GLAXF is priced at $24.66, while GIFLF trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas GIFLF's P/E ratio is 15.66. In terms of profitability, GLAXF's ROE is +0.33%, compared to GIFLF's ROE of +0.08%. Regarding short-term risk, GLAXF is more volatile compared to GIFLF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check GIFLF's competition here
GLAXF vs KYKOF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, KYKOF has a market cap of 7.6B. Regarding current trading prices, GLAXF is priced at $24.66, while KYKOF trades at $14.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas KYKOF's P/E ratio is 18.03. In terms of profitability, GLAXF's ROE is +0.33%, compared to KYKOF's ROE of +0.08%. Regarding short-term risk, GLAXF is less volatile compared to KYKOF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.Check KYKOF's competition here
GLAXF vs OPHLF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, OPHLF has a market cap of 6.8B. Regarding current trading prices, GLAXF is priced at $24.66, while OPHLF trades at $14.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas OPHLF's P/E ratio is 15.65. In terms of profitability, GLAXF's ROE is +0.33%, compared to OPHLF's ROE of +0.09%. Regarding short-term risk, GLAXF is more volatile compared to OPHLF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check OPHLF's competition here
GLAXF vs OPHLY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, OPHLY has a market cap of 6.4B. Regarding current trading prices, GLAXF is priced at $24.66, while OPHLY trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas OPHLY's P/E ratio is 14.74. In terms of profitability, GLAXF's ROE is +0.33%, compared to OPHLY's ROE of +0.09%. Regarding short-term risk, GLAXF is more volatile compared to OPHLY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check OPHLY's competition here
GLAXF vs DPHAY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, DPHAY has a market cap of 5.6B. Regarding current trading prices, GLAXF is priced at $24.66, while DPHAY trades at $98.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas DPHAY's P/E ratio is -155.56. In terms of profitability, GLAXF's ROE is +0.33%, compared to DPHAY's ROE of -0.04%. Regarding short-term risk, GLAXF is more volatile compared to DPHAY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check DPHAY's competition here
GLAXF vs SNPHY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, SNPHY has a market cap of 3.8B. Regarding current trading prices, GLAXF is priced at $24.66, while SNPHY trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas SNPHY's P/E ratio is 16.55. In terms of profitability, GLAXF's ROE is +0.33%, compared to SNPHY's ROE of +0.13%. Regarding short-term risk, GLAXF is more volatile compared to SNPHY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check SNPHY's competition here
GLAXF vs SNPHF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, SNPHF has a market cap of 3.5B. Regarding current trading prices, GLAXF is priced at $24.66, while SNPHF trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas SNPHF's P/E ratio is 15.48. In terms of profitability, GLAXF's ROE is +0.33%, compared to SNPHF's ROE of +0.17%. Regarding short-term risk, GLAXF is more volatile compared to SNPHF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check SNPHF's competition here
GLAXF vs VRBCF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, VRBCF has a market cap of 3.4B. Regarding current trading prices, GLAXF is priced at $24.66, while VRBCF trades at $408.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas VRBCF's P/E ratio is 19.49. In terms of profitability, GLAXF's ROE is +0.33%, compared to VRBCF's ROE of +0.14%. Regarding short-term risk, GLAXF is more volatile compared to VRBCF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check VRBCF's competition here
GLAXF vs HAWPY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, HAWPY has a market cap of 3B. Regarding current trading prices, GLAXF is priced at $24.66, while HAWPY trades at $53.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas HAWPY's P/E ratio is 14.27. In terms of profitability, GLAXF's ROE is +0.33%, compared to HAWPY's ROE of +0.06%. Regarding short-term risk, GLAXF is more volatile compared to HAWPY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check HAWPY's competition here
GLAXF vs HAWPF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, HAWPF has a market cap of 2.7B. Regarding current trading prices, GLAXF is priced at $24.66, while HAWPF trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas HAWPF's P/E ratio is 12.77. In terms of profitability, GLAXF's ROE is +0.33%, compared to HAWPF's ROE of +0.06%. Regarding short-term risk, GLAXF is less volatile compared to HAWPF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.Check HAWPF's competition here
GLAXF vs PTKFF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, PTKFF has a market cap of 2B. Regarding current trading prices, GLAXF is priced at $24.66, while PTKFF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas PTKFF's P/E ratio is N/A. In terms of profitability, GLAXF's ROE is +0.33%, compared to PTKFF's ROE of +0.16%. Regarding short-term risk, GLAXF is more volatile compared to PTKFF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check PTKFF's competition here
GLAXF vs LYPHF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, LYPHF has a market cap of 1.3B. Regarding current trading prices, GLAXF is priced at $24.66, while LYPHF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas LYPHF's P/E ratio is 16.39. In terms of profitability, GLAXF's ROE is +0.33%, compared to LYPHF's ROE of +0.04%. Regarding short-term risk, GLAXF is less volatile compared to LYPHF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.Check LYPHF's competition here
GLAXF vs TGRNF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, TGRNF has a market cap of 633.9M. Regarding current trading prices, GLAXF is priced at $24.66, while TGRNF trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas TGRNF's P/E ratio is 9.90. In terms of profitability, GLAXF's ROE is +0.33%, compared to TGRNF's ROE of +0.05%. Regarding short-term risk, GLAXF is more volatile compared to TGRNF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check TGRNF's competition here
GLAXF vs JCRRF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, JCRRF has a market cap of 383.7M. Regarding current trading prices, GLAXF is priced at $24.66, while JCRRF trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas JCRRF's P/E ratio is 28.59. In terms of profitability, GLAXF's ROE is +0.33%, compared to JCRRF's ROE of +0.06%. Regarding short-term risk, GLAXF is less volatile compared to JCRRF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.Check JCRRF's competition here
GLAXF vs MAYNF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, MAYNF has a market cap of 130M. Regarding current trading prices, GLAXF is priced at $24.66, while MAYNF trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas MAYNF's P/E ratio is -2.13. In terms of profitability, GLAXF's ROE is +0.33%, compared to MAYNF's ROE of -0.23%. Regarding short-term risk, GLAXF is more volatile compared to MAYNF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check MAYNF's competition here
GLAXF vs PTKFY Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, PTKFY has a market cap of 9.7M. Regarding current trading prices, GLAXF is priced at $24.66, while PTKFY trades at $8.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas PTKFY's P/E ratio is 9.64. In terms of profitability, GLAXF's ROE is +0.33%, compared to PTKFY's ROE of +0.16%. Regarding short-term risk, GLAXF is less volatile compared to PTKFY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.Check PTKFY's competition here
GLAXF vs PSYGF Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, PSYGF has a market cap of 2M. Regarding current trading prices, GLAXF is priced at $24.66, while PSYGF trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas PSYGF's P/E ratio is -0.17. In terms of profitability, GLAXF's ROE is +0.33%, compared to PSYGF's ROE of -14.36%. Regarding short-term risk, GLAXF is less volatile compared to PSYGF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.Check PSYGF's competition here
GLAXF vs CRXTQ Comparison June 2026
GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXF stands at 98.9B. In comparison, CRXTQ has a market cap of 72.8K. Regarding current trading prices, GLAXF is priced at $24.66, while CRXTQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXF currently has a P/E ratio of 12.91, whereas CRXTQ's P/E ratio is -0.00. In terms of profitability, GLAXF's ROE is +0.33%, compared to CRXTQ's ROE of +0.33%. Regarding short-term risk, GLAXF is more volatile compared to CRXTQ. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.Check CRXTQ's competition here